Patent Law Firms Face the AI Squeeze as Clients Internalize More Work

As in-house patent teams rethink how work is allocated, the implications for outside counsel are unavoidable. Corporate clients are asking whether work being done by outside counsel is being performed as efficiently as possible and even starting to ask whether it needs to be performed by outside counsel at all. At least some in-house teams are wondering whether the same or better result can be achieved internally using AI-enabled tools. If the answer is yes, then clients can be expected to decrease reliance on outside counsel, looking to law firm attorneys for targeted support, not end-to-end project management.

Beware the Siren’s Call of Industrial Policy

To say we live in perplexing times is an understatement. Everything seems to be shifting beneath our feet, often with seemingly little thought. One example is the move to change how the federal government supports research.

Evaluating the Business Case for AI in Patent Practice

Artificial intelligence has moved beyond the experimental phase in legal practice. The legal industry is no longer debating whether lawyers can or should use AI tools, or whether AI will affect the economics of law firm and in-house legal department operations. Those questions have been answered. AI is already reshaping how legal work is performed, how legal departments manage demand, how law firms are expected to price services, how patent teams analyze portfolios, and how clients evaluate outside counsel.

The Real Cost of Weakening Drug Patents

When the Food and Drug Administration (FDA) approved a new, easier-to-administer version of a popular cancer medicine called Keytruda a few months ago, patients celebrated. But critics quickly cried foul, accusing the drug’s manufacturer of gaming the patent system to preserve its monopoly and prevent cheaper competitors from coming to market. 

Gerasimow Law is Seeking an Associate Attorney

Gerasimow Law is seeking an Associate Attorney to provide core support to a Partner and Senior Associate across a diverse intellectual property docket. This role offers direct involvement in the technical and legal life cycle of a case, from initial filing through post-grant challenges. This position is fully remote with no in-office requirement. Candidates located in Illinois or Texas are a plus.

CAFC Says Generic Hypertension Drug Does Not Infringe Actelion’s Patents

The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision today affirming a district court ruling that Mylan Pharmaceuticals’ generic hypertension drug did not literally infringe Actelion Pharmaceuticals’ U.S. patents for its own hypertension drug, Veletri®. The CAFC also affirmed the district court’s holding that Actelion had not proven and was barred from asserting infringement by an equivalent.

USPTO Targets Removal of 10,500 Trademarks for Fraudulent Submissions, Scam Billing Practices

Yesterday, the U.S. Patent and Trademark Office published a trademark alert highlighting actions that the agency has taken recently to remove fraudulent and otherwise invalid marks from the federal trademark register. In 11 administrative orders issued by the USPTO since the beginning of last October, the agency has either invalidated or is targeting for invalidation around 10,500 trademark applications and registrations for reasons including forged attorney signatures and inventing non-existent trademark registration requirements and fees.

Subscribe to IPWatchdog

This is the best way to stay informed. We send a daily roundup of our latest news, press releases, and events.

Get Email Updates